

# **Drug Level Monitoring**

---

**Analytical Techniques,  
Metabolism, and  
Pharmacokinetics**

---

**Wolfgang Sadée  
and Geertruida C.M. Beelen**

# **DRUG LEVEL MONITORING**

**Analytical Techniques,  
Metabolism,  
and Pharmacokinetics**

**Wolfgang Sadée  
Geertruida C. M. Beelen**

University of California  
San Francisco, California

**A Wiley-Interscience Publication**

**JOHN WILEY & SONS**

**New York • Chichester • Brisbane • Toronto**

Copyright © 1980 by John Wiley & Sons, Inc.

All rights reserved. Published simultaneously in Canada.

Reproduction or translation of any part of this work beyond that permitted by Sections 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc.

*Library of Congress Cataloging in Publication Data*

Sadée, Wolfgang, 1942-

Drug Level Monitoring

"A Wiley-Interscience publication."

Includes index.

1. Drugs—Analysis. 2. Drug metabolism.
3. Pharmacokinetics. I. Beelen, Geertruida C. M., 1946— joint author. II. Title. [DNLM: 1. Drug therapy. 2. Monitoring, Physiologic drug—Analysis. QV25 W859d]

RS189.S15 615.7 79-22652

ISBN 0-471-04881-X

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

# PREFACE

Drug level monitoring represents an important aspect of pharmacologic research. Moreover, the value of drug serum concentrations in optimizing individual drug dosages has led to therapeutic drug level monitoring as a standard clinical practice for many important drugs. This book demonstrates how the principles of drug analysis and drug disposition are combined in drug level monitoring. It serves as a guide to the analytical techniques applicable to drug assays in biological samples, and as a reference source for metabolic and pharmacokinetic data, and is addressed to the analytical and clinical chemist, to the health-care professional specialized in drug therapy—for example the clinical pharmacologist and clinical pharmacist—and to researchers in all areas of pharmacology.

The first four chapters form a general summary of the principles of drug metabolism, pharmacokinetics, clinical pharmacokinetics, therapeutic drug level monitoring, and analytical techniques for biological samples. The specific part, Chapter 5, reviews in detail the analysis and metabolic disposition of approximately 100 selected drugs in a series of monographs. We emphasize the drugs that are currently analyzed in clinical laboratories for therapeutic purposes. Furthermore, representative drugs have been chosen from a large variety of classes—in particular, drugs of abuse, anticancer drugs, antibiotics, cardiovascular drugs, and centrally active drugs. The pertinent literature published before May 1979 is included in the monographs and updated to November 1979 in an addendum.

WOLFGANG SADÉE  
GEERTRUIDA C. M. BEELEN

*San Francisco, California*  
*January 1980*

# ACKNOWLEDGMENTS

We are indebted to the Clinical Chemistry Section at the University of California at San Francisco and to the staff of the Clinical Pharmacokinetics Laboratory, in particular to J. L. Powers, B. R. Stafford, and R. A. Marques, who assisted in the development of this laboratory. The CPL provides services in therapeutic drug level monitoring at UCSF and represents the basis for this book. Several sections and drug monographs were written by J. L. Powers, B. R. Stafford, T. Guentert, and T. L. Ding. Finally, graduate students enrolled in the elective course "Bioanalytical Theory and Techniques" taught by W. Sadée at UCSF in 1978, have contributed to many monographs, and they are mentioned appropriately.

# CONTENTS

## **Introduction**

## **Chapter 1. Drug Metabolism, 3**

## **Chapter 2. Pharmacokinetics, 14**

## **Chapter 3. Clinical Pharmacokinetics and Therapeutic Drug Level Monitoring, 17**

## **Chapter 4. Analytical Techniques, 27**

### **4.1. Current Scope and Future Trends, 27**

### **4.2. Preparation of Biological Specimen for Analysis, 33**

#### **4.2.1. Composition of Blood, Plasma, Serum, Saliva, and Urine**

#### **4.2.2. Work-up Procedures Prior to Analysis**

#### **4.2.3. Chemical Derivatizations**

### **4.3. High-Performance Liquid Chromatography, 42**

### **4.4. Gas Chromatography, 51**

### **4.5. Mass Spectrometry 61**

### **4.6. Thin-Layer Chromatography, 69**

### **4.7. Spectroscopic Methods, 73**

#### **4.7.1. Ultraviolet and Visible Spectroscopy**

#### **4.7.2. Colorimetry**

#### **4.7.3. Fluorescence**

#### **4.7.4. Future Trends**

### **4.8. Polarography, 80**

### **4.9. Competitive Protein Binding Assays, 82**

#### **4.9.1. Radioimmunoassay**

#### **4.9.2. Enzyme Immunoassay**

#### **4.9.3. Other Immunoassays**

#### **4.9.4. Other Competitive Protein Binding Assays**

- 4.10. **Enzymatic Assays**, 97
- 4.11. **Microbiological Assays**, 98
- 4.12. **Various Assay Techniques**, 99
- 4.13. **Assay Evaluation**, 101
- 4.14. **Clinical Pharmacokinetics Laboratory**, 106

**Chapter 5. Drug Monographs**, 108

- Acetaminophen, 108
- Acetazolamide, 117
- $\epsilon$ -Aminocaproic acid, 119
- Aminopyrine, 121
- Amphetamine, 126
- Anticonvulsants, 132
  - Mephobarbital, Phenobarbital, Primidone, Ethotoin, Mephentyoin, Phenytoin, Paramethadione, Trimethadione, Ethosuximide, Methsuximide, Phen-suximide, Carbamazepine
- Atropine, 146
- Barbiturates, 148
  - Amobarbital, Hexobarbital, Mephobarbital, Pentobarbital Sodium, Phenobarbital, Thiopental Sodium
- BCNU, 159
- Carbamazepine, 162
- Chloramphenicol, 167
- Chlordiazepoxide, 172
- Chloroquine, 176
- Chlorpromazine, 180
- Clofibrate, 185
- Clonazepam, 188
- Clonidine, 195
- Cocaine, 198
- Cyclophosphamide, 203
- Dexamethasone, 207
- Diatrizoate Sodium 209
- Diazepam, 212
- Diazoxide, 215
- Digoxin, 218
- Diphenhydramine, 227
- Doxorubicin, 229
- Ethambutol, 236
- Ethosuximide, 239

Ethynylestradiol, 242
5-Fluorouracil, 246
Gentamicin, 251
Haloperidol, 261
Hydralazine, 264
Hydrochlorothiazide, 268
Hydrocortisone, 270
Imipramine, 276
Indomethacin, 280
Isoniazid, 284
Isosorbide Dinitrate, 293
Lidocaine, 296
Lithium Carbonate, 302
Lysergide, 305
Melphalan, 308
Meperidine, 311
6-Mercaptopurine, 314
Methadone, 318
Methaqualone, 322
Methotrexate, 327
Methyldopa, 334
Metronidazole, 338
Morphine, 343
Nicotine, 352
Nitrofurantoin, 358
Oxazepam, 361
Penicillins, 364
Amoxicillin, Ampicillin, Carbenicillin, Cloxacillin, Dicloxacillin, Methicillin, Nafcillin, Oxacillin, Peni- cillin G, Penicillin V
Phencyclidine, 373
Phenylbutazone, 377
Phenytoin, 382
Primidone, 387
Procainamide, 389
Procarbazine, 394
Propoxyphene, 398
Propranolol, 400
Quinidine, 406
Reserpine, 415
Salicylic Acid, 417

## **xii   *Contents***

Spironolactone, 423

Succinylcholine Chloride, 427

Sulfonamides, 431

Sulfacetamide, Sulfanilamide, Sulfapyridine, Sulfathiazole, Sulfisomidine, Sulfisoxazole

Tetracyclines, 441

Doxycycline, Minocycline, Oxytetracycline, Tetracycline

Tetrahydrocannabinol, 447

Theophylline, 453

Tolbutamide, 459

Valproic Acid, 463

Warfarin, 466

Citation Analysis, 471

**Addendum, 472**

**Index, 485**

# INTRODUCTION

The already classical studies on the nature and significance of drug metabolism and disposition by Axelrod, Brodie, Dost, Krüger-Thiemer, and others, conducted only a few decades ago, stimulated an enormous activity in this area. We now recognize that pharmacokinetic parameters determine to a large extent the pharmacological responses of individual patients. Moreover, differences in drug disposition account for a major share of interindividual differences in drug response. Drug doses required to achieve the same response in different patients may vary by more than one order of magnitude. It is for these reasons that drug level monitoring has assumed its present importance in drug research and therapy.

The definition of drug level monitoring also outlines the scope of this book; it is the quantitative determination of drugs and their metabolites in biological specimens and the interpretation of such data using principles of pharmacokinetics and pharmacodynamics. Drug level monitoring thus incorporates the following fields:

- Drug metabolism
- Pharmacokinetics
- Pharmacodynamics
- Pathophysiology
- Drug analysis
- Clinical chemistry
- Clinical toxicology
- Clinical pharmacokinetics and therapeutic drug level monitoring

Detailed investigations on the disposition of a new drug are now required before it can be applied to human clinical trials. Pharmacologic research often utilizes drug level monitoring to study the

## 2 Introduction

mechanism of drug action, including the contribution of metabolites to the drug effect. Furthermore, bioavailability studies depend on drug level monitoring; new drug formulations have to be tested for their bioequivalence in terms of established standard preparations. Drug level monitoring in the area of drug abuse and overdose is again based on a different set of criteria and objectives. However, the most rapid growth at present occurs in the application of drug level monitoring as a guide to optimize individual drug dosage regimens. We will refer to this area as "clinical pharmacokinetics and therapeutic drug level monitoring." Most major hospitals have established clinical chemistry sections devoted to the analysis of therapeutic drug concentrations ("Drug Level Laboratory," "Clinical Pharmacokinetics Laboratory").

We have approached the complex area of drug level monitoring by selecting approximately 100 important, representative drugs. Selection criteria were as follows:

1. Drugs that are currently measured in clinical pharmacokinetics laboratories.
2. Drugs that are representative of a class of chemical or pharmacological agents (e.g.,  $\epsilon$ -aminocaproic acid, chloroquin, clofibrate, ethynylestradiol, isosorbide dinitrate, succinylcholine, warfarin).
3. Drugs that belong to the following major classes: antimicrobials, anticancer drugs, antiepileptics, cardiovascular drugs, psychotropic drugs, analgesics, and drugs of abuse.

The metabolism, pharmacokinetics, and, in more detail, the analytical assays of biological specimens are reviewed in separate monographs for these 100 drugs. In addition, many more drugs listed in the register are close chemical analogs of the selected drugs, and the literature cited often contains detailed information on these analogs as well. The monographs evaluate the literature that is currently available and assist health-care professionals, pharmacologists, and analytical chemists to utilize drug level monitoring to its full potential.

Brief general chapters are designed to introduce the reader to the terminology and scope of pharmacokinetics, drug metabolism, and analytical techniques, while tables enumerate the information contained in the drug monographs for ready cross-referencing. Detailed discussions of the various general areas of interest can be found in the textbooks cited.

# DRUG METABOLISM

Drugs are eliminated from the body either in the unchanged form, usually via renal excretion, or as metabolites. While it is generally assumed that drug metabolites are inactive and more readily excreted by the kidneys than is the parent drug, there are many examples of active or even toxic metabolites. Table I contains the therapeutically relevant metabolites of the listed drugs. Many of these drugs give rise to active or toxic metabolites that need to be considered in drug level monitoring. Major inactive metabolites are also included in Table I, since they may interfere with the drug level assay or can be utilized to indirectly determine the fate of the active species in the body. For example, the urinary excretion of the glucuronide of 4-OH-phenytoin, the major inactive product of phenytoin, can serve to differentiate between rapid metabolism and noncompliance in patients who do not respond to therapy (see phenytoin monograph).

Table I also includes the major mode of elimination of the active drug from the body, that is, renal or metabolic, which is an important parameter in clinical pharmacokinetics. Metabolic elimination means that the active species, either parent drug or active metabolite, is predominantly cleared by metabolic conversion to inactive products, regardless of whether or not these inactive metabolites are then excreted into the urine. For instance, diazepam is sequentially metabolized to the pharmacologically active *N*-desmethyldiazepam and oxazepam, followed by glucuronidation to the inactive oxazepam-3-*O*-glucuronide as the major urinary product. Thus the mode of elimination of active diazepam is by metabolism (see diazepam monograph). The predominance of the metabolic route as the major mode of elimination is striking. Many of the rather inert, lipophilic drugs would possess exceedingly long half-lives in the body were it not for the surprising capacity of mammalian species to metabolize almost any ingested chemical substance.

Table I. Summary of Pharmacokinetic and Metabolic Data on 102 Selected Drugs  
(For further details see individual drug monographs.)

Drug	Active metabolites	Toxic metabolites	Inactive <sup>a</sup> metabolites	Plasma elimination <sup>b</sup> half-life	Plasma levels		Major mode of elimination <sup>d</sup>
					Therapeutic <sup>c</sup>	Toxic	
Acetaminophen		Oxidized intermediates	S-conjugates (overdose)	2 hr, longer after toxic doses 2 ( $\alpha$ ) and 13 ( $\beta$ ) hr ~1 hr	1-10 $\mu$ g/ml	>10 $\mu$ g/ml for days	M
Acetazolamide					~10 $\mu$ g/ml		R
$\epsilon$ -Aminocaproic acid					100-400 $\mu$ g/ml		R
Aminopyrine	4-Aminoantipyrine	4-Formylaminopyrine (?), dimethylnitrosamine	Methylru-bazoic acid	2.7 hr	5 $\mu$ g/ml (peak level)		M
Amphetamine			Phenylacetone	7 hr, acidic urine; 20 hr, basic urine	10 ng/ml (peak level)		M + R
<i>Anticonvulsants<sup>e</sup></i>							
Mephobarbital	Phenobarbital			24-45 hr	Therapeutic levels of phenobarbital 10-30 $\mu$ g/ml		M + R
Phenobarbital					Therapeutic levels of phenobarbital		M + R
Primidone	Phenobarbital, phenylethylmalondiamide			84-108 hr 12 $\pm$ 6 hr			M + R
$\Delta$ -Ethoin							M
Mephentyoin	Phenylethylhydantoin				15-50 $\mu$ g/ml 15-40 $\mu$ g/ml (sum of mephentyoin and phenylethylhydantoin)		M

Phenytoin		4-OH-phenytoin glucuronide	24 ± 12 hr	10-20 µg/ml	M
Paramethadione	Ethylmethyl-oxazolimedione				
Trimethadione	Dimethadione		8 hr (dimethadione) 24-72 hr	>100 µg/ml (as dimethadione) 40-100 µg/ml	M
Ethoxurimide		Oxidative metabolites	2-4 hr	10-40 µg/ml (as <i>N</i> -desmethylmethauximide 5-15 µg/ml Low ng/ml range	M
Methauximide	<i>N</i> -Desmethylmethauximide		4 hr 2(α) and 13-38 (β) hr	1-5 µg/ml	M
Phenauximide				10 µg/ml (hypnotics)	
Atropine					
<i>Barbiturates</i>					
Amobarbital			14-42 hr		M
Hexobarbital	<i>N</i> -Desmethylhexobarbital		3-7 hr		M
Pentobarbital sodium		Hydroxylated metabolites	23-30 hr		M
Thiopental sodium			> 8 hr		M
BCNU	Alkylating and carbamoylating species	Alkylating and carbamoylating species	<15 min		M
Carbamazepine	10,11-Epoxide		18-65 hr (single dose) 10-20 hr (maintenance) 1.5-3.5 hr	5-10 µg/ml	M
Chloramphenicol			20-24 hr (14-95 hr for demoxepam)	20-40 µg/ml (peak levels) 1-3 µg/ml	M
Chlordiazepoxide	<i>N</i> -Desmethylchlordiazepoxide, demoxepam	Oxazepam glucuronide		> 5.5 µg/ml +	M

Table I. (Continued)

Drug	Active metabolites	Toxic metabolites	Inactive <sup>a</sup> metabolites	Plasma elimination <sup>b</sup> half-life	Plasma levels		Major mode of elimination <sup>c</sup>
					Therapeutic <sup>c</sup>	Toxic	
Chloroquine	N-Desethyl chloroquine			3 ( $\alpha$ ) and 18 ( $\beta$ ) days	None defined		M
Chlorpromazine	Monodesmethyl-chlorpromazine, 7-hydroxy-chlorpromazine		Many metabolites	6 hr ( $\alpha$ ), $\beta$ -phase possibly much longer	50-300 ng/ml		M
Clofibrate	Clofibrinic acid		Clofibrinic acid glucuronide	12 hr (clofibrinic acid)	80-200 $\mu$ g/ml (clofibrinic acid)		M
Clonazepam		7-Amino-clonazepam (?)	7-Aminoclonazepam	13-60 hr	5-50 $\mu$ g/ml		M
Clonidine	4-Hydroxy-clonidine			5-23 hr	~1-2 ng/ml		M
Cocaine			Benzoyllecgonine and methylecgonine	30-70 min	200 ng/ml (peak levels)		M
Cyclophosphamide	Aldophosphamide, phosphoramide mustard			5.6-8.4 hr	10-150 ng/ml		M
Dexamethasone			Many metabolites	2.5-6.5 hr	Low ng/ml range		M
Diatrizoate				4 hr	> 100 $\mu$ g/ml (diagnostic)		R
Diazepam	N-Desmethyl-diazepam		Oxazepam glucuronide	26-53 hr	0.1-1.0 $\mu$ g/ml		M
Diazoxide				24-36 hr	15-50 $\mu$ g/ml (in hypoglycemia)		M + R
Digoxin				1.6 days	0.5-2 ng/ml	> 2 ng/ml	R

Diphenhydramine		(Diphenyl-methoxy) acetic acid			M
Doxorubicin	Doxorubicinol	Aglycone metabolites	0.3-1.5 hr ( $\alpha$ )	Low ng/ml range in the $\beta$ -phase	M
Ethambutol		Aldehydes and carboxylic acids	14-30 hr ( $\beta$ )	3-5 $\mu$ g/ml	R
Ethinylestradiol	Estradiol	Glucuronides	4-5 hr	60-500 pg/ml	M
5-Fluorouracil	FdUMP FUTP	$\alpha$ -Fluoro- $\beta$ -alanine (toxic?)	6.5 hr 10 min	0.1-1 $\mu$ g/ml (slow i.v. infusions)	M
Gentamicin		$\beta$ ( $p$ -Fluorobenzoyl)-propionic acid	2-4 hr	> 12 $\mu$ g/ml	R
Haloperidol		Methyltriazolophthalazine	12-39 hr	4-12 $\mu$ g/ml 6-245 ng/ml	M
Hydralazine	Pyruvate and $\beta$ -ketoglutarate hydrazones		1-2 hr	ng/ml range	M
Hydrochlorothiazide		Many metabolites	3-4 hr ( $\alpha$ ), 7-10 hr ( $\beta$ ) 60 min	0.5 $\mu$ g/ml (peak levels) 2-26 $\mu$ g/100 ml (physiolog. conc.)	R
Hydrocortisone		<i>N</i> -Deschlorobenzoyl and <i>O</i> -desmethyl metabolites	4-20 hr 2.6-11.2 hr	15-500 ng/ml 0.5-3 $\mu$ g/ml	M
Imipramine	Desipramine				M
Indomethacin					M
Isoniazid	Acetylhydrazine		45-80 min (fast acetyl.), 140-200 min (slow acetyl.) 30-50 min	$\sim$ 10 $\mu$ g/ml 2-9 ng/ml (peak levels)	M + R
Isosorbide dinitrate	Isosorbide mononitrates (active?)				M
Lidocaine	Monoethylglycine xylidide	Monoethylglycine-xylidide and glycine xylidide (convulsants)	17 min ( $\alpha$ ), 100 min ( $\beta$ )	1.5-7 $\mu$ g/ml > 7 $\mu$ g/ml	M

8 Table I. (Continued)

Drug	Active metabolites	Toxic metabolites	Inactive <sup>a</sup> metabolites	Plasma elimination <sup>a</sup> half-life	Plasma levels		Major mode of elimination <sup>a</sup>
					Therapeutic <sup>c</sup>	Toxic	
Lithium Lysergide			2-Oxy-LSD	15-20 hr 3.5 hr	0.6-1.2 mEq/l 1-5 ng/ml (peak levels)	> 2 mEq/l	R M
Mefpahan	Monohydroxy-melphalan			30 min (dogs)	1 µg/ml (peak level)		M
Meperidine	Normeperidine	Normeperidine (convulsant)		3.2-3.7 hr	0.6 µg/ml	> 5 µg/ml	M
6-Mercaptopurine	Nucleotides of 6-mercaptopurine, 6-methyl mercaptopurine, and 6-thioguanine		Thiouric acid				M
Methadone			N-Demethylated, cyclized metabolites	29 ± 5 hr	100-400 ng/ml		M
Methaqualone			Hydroxylated metabolites	26 hr (α), 37 hr (β), 72 hr (γ)	2-3 µg/ml (peak level)	5-30 µg/ml	M
Methotrexate		7-OH-methotrexate (?)		4-24 hr		> 4.5 × 10 <sup>-8</sup> M for 48 hr	R
Methyldopa	α-Methyldopamine, α-methylnorepinephrine				6 µg/ml (after 1 hr; 250 mg i.v.)		M
Metronidazole		2-Hydroxymethyl-metronidazole, reductive metabolites		6-14 hr	5 µg/ml (antimicrobial), 100-200 µg/ml (radio-sensitizer)		M
Morphine	Normorphine, etc.		Morphine-3-glucucuronide	2 hr (α)	70 ng/ml (peak level) after 10 mg (a.c.)		M